08:13 AM EDT, 10/20/2025 (MT Newswires) -- Disc Medicine ( IRON ) said Monday it ended Q3 with about $616 million in cash, cash equivalents and marketable securities.

On Aug. 7, the company reported that it ended Q2 with $650 million in cash and equivalents.

Among drugs in development, Disc Medicine ( IRON ) said it expects to report initial data from an ongoing phase 2 study of DISC-0974 to treat anemia of myelofibrosis by year-end.

The company said it also expects to establish a phase 2 proof-of-concept of DISC-3405 to treat polycythemia vera and initiate a phase 1b study in sickle cell disease by year-end.

Disc Medicine ( IRON ) shares were 0.2% higher in premarket trading.